Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study

This publication has 17 references indexed in Scilit:

• Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up
  Cancer Immunology, Immunotherapy, 1995
• Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma
  British Journal of Cancer, 1994
• Adoptive immunotherapy of established tumors. Acquisition of radioresistance by tumor‐specific T cells after passive transfer into tumor‐bearing recipients
  International Journal of Cancer, 1994
• Combined betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer
  International Journal of Radiation Oncology*Biology*Physics, 1993
• Interleukin-1 modulatory effect on the action of chemotherapeutic drugs and localized irradiation of the lip, duodenum, and tumor
  International Journal of Radiation Oncology*Biology*Physics, 1993
• Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model
  Journal of Neuro-Oncology, 1993
• Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Synergy of Radiation Therapy and Immunotherapy in Murine Renal Cell Carcinoma
  Journal of Urology, 1992
• Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.
  The Journal of Experimental Medicine, 1990
• Characterization of recombinant glycosylated human interleukin 2 produced by a recombinant plasmid transformed CHO cell line
  FEBS Letters, 1987